#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Stargardt's disease VEXAS syndrome Spinal muscular atrophy Congenital pseudarthrosis Cardiac amyloidosis Rett syndrome Inclusion body myositis Chronic graft versus host disease in skin Infantile spasms Crohn's disease Osteosarcoma Hepatic angiosarcoma Immune-mediated myasthenia gravis Liver abscess Cholangitis sclerosing More trials…

    Learn about Rare Diseases

    Hereditary angioedema with C1 esterase inhibitor deficiency – Diagnostics Systemic mastocytosis – Treatment Leiomyosarcoma recurrent – Diagnostics Mastocytosis – Treatment Chondrosarcoma metastatic – Life with Disease Piriformis syndrome – Treatment Waldenstrom’s macroglobulinaemia recurrent – Treatment Mucopolysaccharidosis II – Life with Disease Skin angiosarcoma – Life with Disease Ehlers-Danlos syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gefitinib Cimetidine RIKKUNSHITO Omp11 Trastuzumab Emtansine Candesartan Daptomycin Oms906 Brexucabtagene Autoleucel Atorvastatin Calcium Sodium Chloride MZE829 IDP-121 VELPATASVIR Lovo-B Petosemtamab AUROCELL-TX Chlorpromazine Hydrochloride Fluoroestradiol F-18 Rbl007.2 More therapies…

    Learn about Your Condition

    Hepatic encephalopathy Haemoglobinuria Pulmonary alveolar haemorrhage Chorea Rhabdomyosarcoma Hydrocele Neonatal hyperglycaemia Binge eating Skin disorder Biopsy heart Vesicoureteric reflux MELAS syndrome Viral infection Medulloblastoma recurrent Embolism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Immune system processes

  • Study on the Safety of Long-Term Use of Deucrictibant for Treating Hereditary Angioedema Attacks in Patients with C1-Inhibitor Deficiency

    Recruiting

    4 1 1
    Investigated Diseases:
    • Hereditary angioedema with C1 esterase inhibitor deficiency
    Investigated Drugs:
    • (S)-N-(1-Deutero-1-(3-Chloro-5-Fluoro-2-((2-Methyl-4-(1-Methyl-1H-1,2,4-Triazol-5-Yl)Quinolin-8-Yloxy)Methyl)Phenyl)Ethyl)-2-(Difluoromethoxy)Acetamide
    • Icatibant
    • Deucrictibant
    Austria Bulgaria Czechia France Germany Hungary +8

  • Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated Drugs:
    • Anhydrous Caffeine
    • Camphor
    • Dapirolizumab Pegol
    Belgium Denmark France Germany Greece Italy +3

  • Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Anhydrous Caffeine
    • Camphor
    • Dapirolizumab Pegol
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms

    Recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Belgium Bulgaria Czechia France Germany Italy +4

  • Study of atrasentan in children aged 2 to <18 years with primary IgA nephropathy to evaluate proteinuria reduction, safety and tolerability

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • IgA nephropathy
    Investigated Drugs:
    • Atrasentan Hydrochloride
    France Spain

  • Evaluation of zirconium-89 crefmirlimab berdoxam PET imaging for monitoring renal allograft rejection in kidney transplant recipients

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    • Kidney transplant rejection
    Investigated Drugs:
    • Zirconium (89Zr) Crefmirlimab Berdoxam
    The Netherlands
Previous Page
1 2 3 4 5 6 … 15
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!